Study of HuMax-CD20, a New Drug to Treat Early Stage Non-Hodgkin´s Follicular Lymphoma

This study has been withdrawn prior to enrollment.
(Acquired asset)
Sponsor:
Information provided by:
GlaxoSmithKline
ClinicalTrials.gov Identifier:
NCT00092274
First received: September 22, 2004
Last updated: April 20, 2015
Last verified: January 2005